TMO · 10-Q · 2026Q3

THERMO FISHER SCIENTIFIC INC.

Filed 2026-10-30 · Industrials · View original filing on EDGAR

Everything TMO's SEC filings said, ranked

Ranked Events

• Acquisitions and DivestituresImportance 65 · Surprise 60
  On March 24, 2026, Thermo Fisher acquired Clario Holdings, a U.S. clinical-trial endpoint data provider, for its Laboratory Products and Biopharma Services segment. The acquisition contributed to $425 million of…
• Income Tax Rate ChangesImportance 59 · Surprise 82
  The third-quarter 2026 GAAP tax rate was 16.9%, compared with 11.3% a year earlier, and the adjusted rate was 11.6%, compared with 11.0%. A $161 million deferred tax benefit from recognized tax attributes related to a…
• Guidance / OutlookImportance 54 · Surprise 24
  Thermo Fisher expects 2026 GAAP effective tax rates of 9% to 11% and an adjusted tax rate of approximately 11.5%. The forecast reflects currently expected profitability across the countries where the company operates…
• Share Repurchase ProgramImportance 52 · Surprise 56
  The company repurchased $4.00 billion of common stock, or 6.9 million shares, in the first nine months of 2026, compared with $3.00 billion, or 5.8 million shares, in the prior-year period. All 2026 repurchases were…
• Capital ExpendituresImportance 52 · Surprise 40
  Thermo Fisher spent $1.26 billion on property, plant and equipment for capacity and capability investments in the first nine months of 2026, compared with $1.06 billion in the prior-year period. The company expected…
• Operating Cash Flow TrendsImportance 52 · Surprise 56
  Net cash provided by operating activities increased to $5.867 billion in the first nine months of 2026 from $4.361 billion in the comparable 2025 period. Free cash flow rose to $4.618 billion from $3.319 billion, while…
• Capital Expenditure OutlookImportance 42 · Surprise 24
  For all of 2026, Thermo Fisher expects property, plant and equipment expenditures, net of disposals, to be between $1.9 billion and $2.0 billion. The company says these investments support capacity and capability.…
• Liquidity and Debt PositionImportance 42 · Surprise 14
  At September 26, 2026, Thermo Fisher held $5.461 billion of cash and cash equivalents, down from $9.852 billion at December 31, 2025, and reported total debt of $41.370 billion, up from $39.384 billion. Short-term…
• Revenue Performance and MixImportance 36 · Surprise 14
  Third-quarter 2026 revenue was $12.137 billion, up 9.1% from $11.122 billion a year earlier; revenue for the first nine months was $35.136 billion, up 8.6% from $32.341 billion. Third-quarter segment revenue was $6.863…
• Clinical Research and Services DemandImportance 32 · Surprise 24
  Laboratory Products and Biopharma Services’ third-quarter organic revenue growth was primarily due to the pharma services business, research and safety market channel, and clinical research business. For the first nine…
• Instrument and Bioproduction DemandImportance 32 · Surprise 24
  Life Sciences Solutions’ organic revenue growth in the third quarter and first nine months of 2026 was driven by bioproduction, with higher demand from pharma and biotech customers. Analytical Instruments’ organic…
• Gross Margin DriversImportance 31 · Surprise 40
  Consolidated GAAP operating margin increased to 18.6% in the third quarter of 2026 from 17.4% in the prior-year quarter and to 17.7% for the first nine months from 17.0%. Adjusted operating margin rose to 24.5% in the…
• Diagnostics Product MomentumImportance 26 · Surprise 24
  Specialty Diagnostics’ organic revenues were flat in the third quarter of 2026. Organic revenue increased in the first nine months, led by the transplant diagnostics and immunodiagnostics businesses. The filing…
• Geographic Market CommentaryImportance 26 · Surprise 24
  In the third quarter of 2026, sales increased across all major geographies. Growth was strong in North America and Europe and very strong in Asia-Pacific, including China. For the first nine months, sales grew in North…
• End-Market Demand TrendsImportance 26 · Surprise 24
  In the third quarter of 2026, pharma and biotech demand was very strong as underlying market conditions continued to strengthen, while academic and government revenues were flat. Industrial and applied revenue was very…

Revenue by Product (in millions)

Revenue by Geography (in millions)